Table 1. Main clinical characteristics of the renal graft recipients

|  |  |  |
| --- | --- | --- |
| Parameter | Recipients with a history of COVID-19 (n = 68) | Recipients without any history of clinical manifestations of COVID-19 (n = 112) |
| Age, median (min – max), years | 47 (26–66) | 50 (20–72) |
| Gender, M/F, N (%) | 37 (54.4) / 31 (45.6) | 80 (71.42) / 32 (28.57) |
| Time after the transplantation, median (min – max), months | 86 (2–225) | 70.5 (15–318) |
| Basic immunosuppressive treatment: tacrolimus / cyclosporin А, N (%) | 52 (76.4) / 13 (19.1) | 93 (83) / 23 (20.53) |

Table 2. The incidence of COVID-19 in renal transplant recipients depending on the presence of viral skin disease

|  |  |  |
| --- | --- | --- |
| Skin disorders, localization | COVID-19 incidence, N (%) | P value |
| Skin disorders positive | Skin disorders negative |
| HPV-associated signs: | 34/112 (30.4) | 34/68 (50.0) | 0.011 |
| Papillomas | 26/92 (28.3) | 42/88 (47.7) | 0.009 |
| Head, neck | 10/46 (21.7) | 58/134 (43.3) | 0.013 |
| Trunk | 9/26 (34.6) | 59/154 (38.3) | 0.828 |
| Upper extremities | 7/17 (41.2) | 61/163 (37.4) | 0.796 |
| Lower extremities | 0/3 (0) | 68/177 (38.4) | 0.291 |
| Seborrheic keratosis | 5/10 (50.0) | 63/170 (37.1) | 0.507 |
| Head, neck | 3/5 (60.0) | 65/175 (37.1) | 0.368 |
| Trunk | 2/5 (40.0) | 66/175 (37.7) | 1 |
| Upper extremities | 1/2 (50.0) | 67/178 (37.6) | 1 |
| Lower extremities | 0/1 (0) | 68/179 (38.0) | 1 |
| Warts | 5/10 (50.0) | 63/170 (37.1) | 0.507 |
| Head, neck | 0/0 | 68/180 (37.8) | 1 |
| Trunk | 0/0 | 68/180 (37.8) | 1 |
| Upper extremities | 3/7 (42.9) | 65/173 (37.6) | 1 |
| Lower extremities | 2/4 (50.0) | 66/176 (37.5) | 0.634 |
| Herpes virus 1, 2-associated | 29/70 (41.4) | 39/110 (35.5) | 0.435 |
| Herpes labialis | 29/57 (50.9) | 39/123 (31.7) | 0.020 |
| Herpes genitalis | 5/10 (50.0) | 63/170 (37.1) | 0.507 |
| Skin and mucosal herpes | 3/4 (75.0) | 65/176 (36.9) | 0.152 |

HPV, human papilloma virus

Table 3. The incidence of COVID-19 in renal transplant recipients depending on seropositivity to some viruses

|  |  |  |
| --- | --- | --- |
| Viral infection | COVID-19 incidence, N (%) | P value |
| Immunoglobulins M and/or G against viruses positive | Immunoglobulins M and G against viruses negative |
| Herpes simplex virus 1, 2 | 15/37 (40.5) | 53/143 (37.1) | 0.707 |
| Cytomegalovirus | 35/90 (38.9) | 33/90 (36.7) | 0.878 |
| Epstein-Barr virus | 28/107 (26.2) | 40/73 (54.8) | 0.0002 |
| SARS-CoV-2 | 62/77 (80.5) | 6/103 (5.8) | < 0.0001 |